MELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at maximising shareholder value. Strategic initiatives under consideration may include, but are not limited to mergers, acquisitions, licensing, or other strategic transactions. There can be no assurance that the strategic process will result in any tr
Detailed price information for Immuron Ltd ADR (IMRN-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Real-time index price for TSX Venture Composite Index (JX), along with buy or sell indicators, analysis, charts, historical performance, news and more
Immuron (NASDAQ:IMRN) has secured exclusive U. S.
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26. The overall U.S. digestive/gut health supplement market is valued at $4.16 billion (Mordor Intelligence). Immuron is targeting a subset of this market with PROIBS®. PROIBS® is a medical device used for abdominal pai
MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectationsIn February 2026 at the time the Company announced a Strategic Reset, 2H FY26 and FY26 Net Sales were projected to both exceed the prior comparative period (pcp) and Net Sales and Net Profit were all projected to exceed pcp. Immuron has exceeded sales projections with second half growth of
This is the newest page. Registered accounts read further back.